Breaking News Instant updates and real-time market news.

AVXS

AveXis

$44.55

2.36 (5.59%)

07:42
10/06/16
10/06
07:42
10/06/16
07:42

AveXis attractive acquisition target, price target to $71 at Goldman

Goldman analyst Salveen Richter said AveXis has two approaching catalysts coming up, the AVXS-101 update in SMA Type 1 at the World Muscle Society, or WMS, on October 8, and clarity on the AVXS-101 pivotal trial design in late October/early November. The analyst expects positive WMS data and raaised his probability of success to 60% from 45%. He expects compelling motor milestone data and pivotal trial visibility to make AveXis an attractive acquisition target and raised his price target to $71 from $46 on shares and reiterated his Buy rating.

  • 06

    Nov

AVXS AveXis
$44.55

2.36 (5.59%)

08/17/16
WELS
08/17/16
UPGRADE
WELS
Outperform
AveXis upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded AveXis (AVXS) to Outperform after speaking to five experts in spinal muscular atrophy. The experts were impressed with both Ionis Pharmaceuticals (IONS)/Biogen's (BIIB) nusinersen and AveXis' gene therapy AVXS101, and suggested that likely incomplete restoration of normal neuromuscular phenotype could prompt combination use of both treatments, Birchenough tells investors in a research note. The analyst raised his price target range for AveXis shares to $56-$61 from $30-$32. The stock closed yesterday down $1.91 to $41.66.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies thinks it found baby in AveXis trial that is walking
Jefferies analyst Biren Amin believes a video posted online of a baby walking has a "strong likelihood" of being a patient in AveXis' AVXS-101 trial. AVXS-101 is a gene therapy candidate in Phase I testing for spinal muscular atrophy. The near 20 month old's achievement to walk "is significant" given that she is a Type 1 SMA baby with 2 copy number and would not in any normal circumstance be expected to walk, Amin tells investors in a research note. The analyst points out that his finding online comes ahead of AveXis' plan to disclose patient data on motor milestones from its Phase 1 trial later this year. To reflect increased confidence in AVXS-101's prospects, Amin raised his price target for the shares to $50 from $42. The clinical-stage gene therapy company, formerly known as Biolife Cell Bank, closed Friday up 83c to $41.72.
09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.

TODAY'S FREE FLY STORIES

KND

Kindred Healthcare

$11.50

0.25 (2.22%)

17:04
06/28/17
06/28
17:04
06/28/17
17:04
Hot Stocks
Kindred Healthcare to partner on new Montana rehabilitation hospital »

Kindred Healthcare,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGI

Logitech

$37.02

0.46 (1.26%)

17:02
06/28/17
06/28
17:02
06/28/17
17:02
Hot Stocks
Logitech nominates to new directors, proposes 10% dividend increase »

Logitech announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

BLCM

Bellicum Pharmaceuticals

$13.32

0.18 (1.37%)

17:00
06/28/17
06/28
17:00
06/28/17
17:00
Syndicate
Breaking Syndicate news story on Bellicum Pharmaceuticals »

Bellicum files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

XLF

Financial Select Sector

$24.52

0.38 (1.57%)

17:00
06/28/17
06/28
17:00
06/28/17
17:00
Technical Analysis
Technical View: Financial Select Sector rises in extended trading »

The Financial Select…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$65.18

0.95 (1.48%)

16:58
06/28/17
06/28
16:58
06/28/17
16:58
Technical Analysis
Technical View: Citi rises after hours »

In the extended session…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 14

    Jul

  • 20

    Jul

  • 25

    Jul

BAC

Bank of America

$23.88

0.61 (2.62%)

16:54
06/28/17
06/28
16:54
06/28/17
16:54
Hot Stocks
Bank of America to boost quarterly dividend 60%, authorizes $12B share buyback »

Bank of America announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNSL

Consolidated Communications

$21.27

0.53 (2.56%)

, FRP

FairPoint

$15.50

0.5 (3.33%)

16:54
06/28/17
06/28
16:54
06/28/17
16:54
Hot Stocks
Consolidated Communications-FairPoint merger secures regulatory approvals »

Consolidated…

CNSL

Consolidated Communications

$21.27

0.53 (2.56%)

FRP

FairPoint

$15.50

0.5 (3.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.24

2.66 (1.77%)

16:54
06/28/17
06/28
16:54
06/28/17
16:54
Periodicals
Facebook creating ad targeting for families, Axios reports »

Facebook is creating new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

NTRS

Northern Trust

$96.66

1.24 (1.30%)

16:52
06/28/17
06/28
16:52
06/28/17
16:52
Hot Stocks
Northern Trust to increase dividend to 42c per share, buy back $750M in stock »

Northern Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

SBOT

Stellar Biotechnologies

$1.23

-0.05 (-3.91%)

16:51
06/28/17
06/28
16:51
06/28/17
16:51
Hot Stocks
Breaking Hot Stocks news story on Stellar Biotechnologies »

Frank R. Oakes reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$71.94

0.14 (0.19%)

16:51
06/28/17
06/28
16:51
06/28/17
16:51
Hot Stocks
Comerica plans to increase dividend 15%, buy back up to $605M of common stock »

Comerica announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$89.82

1.77 (2.01%)

16:50
06/28/17
06/28
16:50
06/28/17
16:50
Hot Stocks
JPMorgan to up quarterly dividend to 56c/share, authorizes $19.4B share buyback »

JPMorgan Chase & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jul

  • 12

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

BBVA

Banco Bilbao

$8.54

0.16 (1.91%)

16:50
06/28/17
06/28
16:50
06/28/17
16:50
Hot Stocks
BBVA Compass receives no objection to its 2017 capital plan »

BBVA Compass Bancshares,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

ZION

Zions Bancorp

$42.97

0.43 (1.01%)

16:49
06/28/17
06/28
16:49
06/28/17
16:49
Hot Stocks
Zions to boost common dividend to 24c per share by 2Q18 »

The Board of Governors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNC

PNC Financial

$123.40

2.28 (1.88%)

16:48
06/28/17
06/28
16:48
06/28/17
16:48
Hot Stocks
PNC says proposed capital plans include 36% dividend hike, $2.7B in buybacks »

The PNC Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jul

MBUU

Malibu Boats

$25.75

0.28 (1.10%)

16:47
06/28/17
06/28
16:47
06/28/17
16:47
Hot Stocks
Malibu Boats to acquire Cobalt Boats for $130M »

Malibu Boats announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIT

CIT Group

$48.61

0.27 (0.56%)

16:47
06/28/17
06/28
16:47
06/28/17
16:47
Hot Stocks
CIT Group receives no objection to its 2017 capital plan »

CIT Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DFS

Discover

$61.88

0.81 (1.33%)

16:47
06/28/17
06/28
16:47
06/28/17
16:47
Hot Stocks
Discover to boost quarterly dividend to 35c per share, authorizes $2.23B buyback »

Discover Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

AMZN

Amazon.com

$990.33

13.55 (1.39%)

, WMT

Wal-Mart

$76.51

0.5 (0.66%)

16:46
06/28/17
06/28
16:46
06/28/17
16:46
Periodicals
Amazon holds first ever 'meet and greet' for sellers, Bloomberg says »

Amazon (AMZN) is holding…

AMZN

Amazon.com

$990.33

13.55 (1.39%)

WMT

Wal-Mart

$76.51

0.5 (0.66%)

EBAY

eBay

$35.31

0.4 (1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

STI

SunTrust

$56.09

0.88 (1.59%)

16:46
06/28/17
06/28
16:46
06/28/17
16:46
Hot Stocks
SunTrust boosts quarterly dividend 54%, authorizes $1.32B share buyback »

SunTrust Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

KEY

KeyCorp

$18.38

0.18 (0.99%)

16:44
06/28/17
06/28
16:44
06/28/17
16:44
Hot Stocks
KeyCorp to boost quarterly dividend to 10.5c per share, to repurchase $800M »

KeyCorp announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$50.60

0.92 (1.85%)

16:43
06/28/17
06/28
16:43
06/28/17
16:43
Hot Stocks
BNY Mellon to raise dividend 24%, repurchase up to $3.1B of common stock »

BNY Mellon announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

CFG

Citizens Financial

$35.34

0.5 (1.44%)

16:42
06/28/17
06/28
16:42
06/28/17
16:42
Hot Stocks
Citizens Financial plans 18c per share quarterly dividends, $850M share buyback »

Citizens Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

FITB

Fifth Third

$25.49

0.4 (1.59%)

, VNTV

Vantiv

$63.47

1.09 (1.75%)

16:41
06/28/17
06/28
16:41
06/28/17
16:41
Hot Stocks
Fifth Third to raise dividend to 16c, repurchase $1.161B of common stock »

Fifth Third Bancorp…

FITB

Fifth Third

$25.49

0.4 (1.59%)

VNTV

Vantiv

$63.47

1.09 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

BBT

BB&T

$44.78

0.96 (2.19%)

16:41
06/28/17
06/28
16:41
06/28/17
16:41
Hot Stocks
BB&T says proposed capital plans include 10% dividend hike, $1.88B in buybacks »

BB&T announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

  • 19

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.